Mutational landscape reflects the biological continuum of plasma cell dyscrasias.
Rossi A et al. Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19.
Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients – Data from the German Calciphylaxis Registry.
Rothe H et al. PLoS One. 2017 Feb 17;12(2):e0172407. doi: 10.1371/journal.pone.0172407. eCollection 2017.
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.
Vuckovic S et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14561. [Epub ahead of print].
Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase.
Baek SH et al. Molecules. 2017 Feb 13;22(2). pii: E276. doi: 10.3390/molecules22020276.
Nanoparticle delivery systems, general approaches and their implementation in Multiple Myeloma.
de la Puente P et al. Eur J Haematol. 2017 Feb 16. doi: 10.1111/ejh.12870. [Epub ahead of print].
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Giuliani M et al. Oncotarget. 2017 Feb 9. doi: 10.18632/oncotarget.15234. [Epub ahead of print].
Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
Momose I et al. J Antibiot (Tokyo). 2017 Feb 15. doi: 10.1038/ja.2017.9. [Epub ahead of print].
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
Perez C et al. J Med Chem. 2017 Feb 13. doi: 10.1021/acs.jmedchem.6b01379. [Epub ahead of print].
The role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma.
Jacobs JF et al. Clin Pharmacol Ther. 2017 Feb 10. doi: 10.1002/cpt.665. [Epub ahead of print].
A novel cholesterol/lipid delivery system for murine myeloma cell lines.
Chauhan G et al. Biotechnol Prog. 2017 Feb 10. doi: 10.1002/btpr.2441. [Epub ahead of print].
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E et al. Leukemia. 2017 Feb 10. doi: 10.1038/leu.2017.54. [Epub ahead of print].
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S et al. Cancer Sci. 2017 Feb 6. doi: 10.1111/cas.13183. [Epub ahead of print].
Autocrine and paracrine interactions between multiple myeloma cells and bone marrow stromal cells by growth arrest-specific gene 6 crosstalk with interleukin-6.
Furukawa M et al. J Biol Chem. 2017 Jan 31. pii: jbc.M116.733030. doi: 10.1074/jbc.M116.733030. [Epub ahead of print].
Bone marrow microenvironment derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA et al. Blood. 2017 Feb 1. pii: blood-2016-10-745059. doi: 10.1182/blood-2016-10-745059. [Epub ahead of print].
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M et al. Oncotarget. 2017 Feb 7;8(6):10213-10224. doi: 10.18632/oncotarget.14378.
Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR et al. Leukemia. 2017 Jan 31. doi: 10.1038/leu.2016.379. [Epub ahead of print].
Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.
Xia J et al. EBioMedicine. 2017 Feb 16. pii: S2352-3964(17)30070-1. doi: 10.1016/j.ebiom.2017.02.011. [Epub ahead of print].
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P et al. Curr Cancer Drug Targets. 2017 Feb 22. doi: 10.2174/1568009617666170222125035. [Epub ahead of print].
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.
Wang D et al. Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.69. [Epub ahead of print].
Regulation of STAT3 and NF-κB Activations by S-Nitrosylation in Multiple Myeloma.
Kim J et al. Free Radic Biol Med. 2017 Feb 20. pii: S0891-5849(17)30111-9. doi: 10.1016/j.freeradbiomed.2017.02.039. [Epub ahead of print].
Enhancing the Anti-Multiple Myeloma Efficiency in a Cancer Stem Cell Xenograft Model by Conjugating the ABCG2 Antibody with Microbubbles for a Targeted Delivery of Ultrasound Mediated Epirubicin.
Shi F et al. Biochem Pharmacol. 2017 Feb 20. pii: S0006-2952(17)30091-6. doi: 10.1016/j.bcp.2017.02.014. [Epub ahead of print].